Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc. insiders are currently net sellers of JNCE stock, showing bearish sentiment over the past 90 days. Total sales of $42.6M outpace purchases of $100.6K, creating a net outflow of $42.5M.

Jounce Therapeutics, Inc. has 18 active insiders who have filed SEC Form 4 transactions in the past 90 days. Kevin C. Tang (Executive) leads with 2 transactions totaling $107.2M. Biosciences, Llc Concentra (Executive) follows with 1 transactions worth $97.4M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Jounce Therapeutics, Inc.'s current score of 0/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on May 3, 2023, when C. Drapkin Kimberlee (Executive) disposed of 25,751 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, JNCE insider trading sentiment is currently bearish with an Alignment Score of 0/100. The negative net flow of $42.5M shows more selling than buying. However, 2% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Jounce Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At JNCE, we track all Form 4 filings—currently showing 156 transactions from 18 insiders over 90 days.

A 10b5-1 plan allows Jounce Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At JNCE, approximately 2% of recent transactions are 10b5-1 trades. The remaining 98% are discretionary trades, which may carry more informational value.

You can monitor Jounce Therapeutics, Inc. (JNCE) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 18 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Jounce Therapeutics, Inc.'s current score of 0/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $100.6K in purchases versus $42.6M in sales over 90 days, resulting in a net flow of -$42.5M.

SEC Form 4 filings are mandatory reports that Jounce Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At JNCE, the most common type is "S" with 25 occurrences. The most recent Form 4 was filed on May 3, 2023 by C. Drapkin Kimberlee.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Jounce Therapeutics, Inc., approximately 2% of recent transactions are executed under 10b5-1 plans, while 98% appear to be discretionary trades. The low percentage means most insider activity at JNCE represents discretionary decisions with more informational value.